Champions Oncology, Inc. (2I3.F)
- Previous Close
5.15 - Open
5.55 - Bid 4.98 x --
- Ask 5.15 x --
- Day's Range
5.15 - 5.55 - 52 Week Range
3.36 - 11.10 - Volume
500 - Avg. Volume
0 - Market Cap (intraday)
71.209M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
12.88 - EPS (TTM)
0.40 - Earnings Date Jul 16, 2025 - Jul 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
www.championsoncology.comRecent News: 2I3.F
View MorePerformance Overview: 2I3.F
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2I3.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2I3.F
View MoreValuation Measures
Market Cap
70.45M
Enterprise Value
73.31M
Trailing P/E
12.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.39
Price/Book (mrq)
14.74
Enterprise Value/Revenue
1.42
Enterprise Value/EBITDA
9.85
Financial Highlights
Profitability and Income Statement
Profit Margin
10.97%
Return on Assets (ttm)
14.64%
Return on Equity (ttm)
376.84%
Revenue (ttm)
58.59M
Net Income Avi to Common (ttm)
6.43M
Diluted EPS (ttm)
0.40
Balance Sheet and Cash Flow
Total Cash (mrq)
3.2M
Total Debt/Equity (mrq)
117.70%
Levered Free Cash Flow (ttm)
-3.45M